• Noninvasive Prenatal Genetic Testing: Cutting Edge Technology Portends New Wrongful Life/Birth Theories of Liability against Healthcare Providers, Labs & Diagnostic Companies
  • August 29, 2017
  • Noninvasive prenatal testing (“NIPT”) is a popular option for high risk pregnancy patients desiring to screen for chromosomal abnormalities.1 By analyzing fetal DNA circulating within the maternal blood, NIPT does not require an invasive procedure that involves extraction of fetal cells for chromosomal analysis; rather, it involves a simple blood test. The patient who elects NIPT can avoid the procedurerelated risk–albeit small–of miscarriage that accompanies amniocentesis and chorionic villous sampling. Through direct-to-consumer advertising, manufacturers of NIPT kits are dominating the market for prenatal screening. NIPT use has quickly penetrated clinical practice, and it has become the screening test of choice for fetal aneuploidy.2